(Q36926621)

17 August 2017

1 reference

title

Global burden of COPD: risk factors, prevalence, and future trends (English)

1 reference

chronic obstructive pulmonary disease

17 August 2017

main subject

1 reference

David M Mannino

1

0 references

author name string

A Sonia Buist

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

370

1 reference

17 August 2017

issue

9589

1 reference

17 August 2017

page(s)

765-773

1 reference

Chronic obstructive pulmonary disease

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Burden and clinical features of chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Smokers with airway obstruction are more likely to quit smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Improving the care of COPD patients — suggested action points by the COPD exacerbations taskforce for reducing the burden of exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

What have we learned from large drug treatment trials in COPD?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

COPD exacerbations: defining their cause and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Systemic Effects of Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Chronic obstructive pulmonary disease severity and cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Anxiety and depression in COPD patients: The roles of gender and disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Use of spirometry and respiratory drugs in Manitobans over 35 years of age with obstructive lung diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Pathophysiology of airflow limitation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

The British hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Update on the "Dutch hypothesis" for chronic respiratory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Alpha1-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

COPD: overview of definitions, epidemiology, and factors influencing its development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Nosology for our day: its application to chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Usefulness of GOLD classification of COPD severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

The natural history of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

COPD: the dangerous underestimate of 15%

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Effects of glutathione S-transferase M1, maternal smoking during pregnancy, and environmental tobacco smoke on asthma and wheezing in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Smoked marijuana as a cause of lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

The occupational burden of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Lung function decline and outcomes in an elderly population.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Trends in the leading causes of death in the United States, 1970-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Gender and COPD in patients attending a pulmonary clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Epidemiology of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Area deprivation predicts lung function independently of education and social class

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Association between self-reported childhood socioeconomic position and adult lung function: findings from the British Women's Heart and Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Interpreting COPD prevalence estimates: what is the true burden of disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Global burden of COPD: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

COPD in Japan: the Nippon COPD Epidemiology study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Mortality in COPD: Role of comorbidities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Pharmacoeconomic evaluation of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

The burden of COPD in Italy: results from the Confronting COPD survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Epidemiology and costs of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Costs of chronic bronchitis and COPD: a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Pharmacoeconomic Evaluation of Acute Exacerbations of Chronic Bronchitis and COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

1 reference

7 January 2021

Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Systemic effects of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Incidence of chronic obstructive pulmonary disease, and the relationship between age and smoking in a Japanese population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

Chronic obstructive pulmonary disease: current burden and future projections.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961380-4

7 January 2021

10.1016/S0140-6736(07)61380-4

Identifiers

DOI

1 reference

17 August 2017

1 reference